Energizer Personal Care – Playtex Manufacturing, Inc. announced today that, out of an abundance of caution, it is adding an adapter production lot to its voluntary nationwide recall of certain AC/DC power adapters that are used with the Playtex® Nurser Deluxe Double Electric Breast Pump.

Trimel Pharmaceuticals Corporation (TSX: TRL) announced today top-line results of its Phase II clinical trial evaluating the efficacy and safety of Tefina™, a “use-as-required” testosterone nasal gel for the treatment of Female Orgasmic Disorder (FOD).

Apotex had initiated a voluntary Type II recall to the retail and pharmacy level for Alysena™ 28 (lot LF01899A), on behalf of the fabricator, Laboratorios Leon Farma SA, due to the potential for a packaged unit to contain two rows of placebo instead of one row (14 tablets instead of 7 tablets) and two rows of active contraceptive tablets (14 tablets instead of 21 tablets) in the blister pack.

Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.

Pfizer Inc. announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.

Pfizer Inc. announced that it has voluntarily recalled 14 lots of Lo/ Ovral-28 ( norgestrel and ethinyl estradiol ) Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic)for customers in the U.S. market.

Researchers funded by the National Institutes of Health have identified a key step in the establishment of a pregnancy.